OncoMatch/Clinical Trials/NCT06055439
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Is NCT06055439 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies CHM-2101 CAR-T cells for neuroendocrine tumors.
Treatment: CHM-2101 CAR-T cells — The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroendocrine Tumor
Colorectal Cancer
Gastric Cancer
Biomarker criteria
Required: CDH17 overexpression (CDH17+)
for gastric adenocarcinoma patients only, central laboratory confirmation of CDH17+ tumor expression is required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic anti-cancer treatment — locally advanced or metastatic
Have received at least 1 prior line of systemic anti-cancer treatment in the locally advanced or metastatic setting
Cannot have received: CDH17-targeted therapy
Previous treatment with CDH17-targeted therapies
Lab requirements
Blood counts
White blood cell count > 4,000/mm3; ANC ≥ 1,500/mm3; Platelets ≥ 100,000/mm3; Hemoglobin ≥ 10 g/dL
Kidney function
Creatinine clearance by Cockroft-Gault equation 60 mL/min
Liver function
Total bilirubin ≤ 1.5 x ULN; AST ≤ 3 x ULN; ALT ≤ 3 x ULN; Albumin ≥ 3 g/dL
Cardiac function
Left ventricular ejection fraction ≥ 50%
Minimum Laboratory Values for Study Entry Laboratory Assessment Criteria White blood cell count > 4,000/mm3 Absolute neutrophil count (ANC) ≥ 1,500/mm3 Platelets ≥ 100,000/mm3 Hemoglobin ≥ 10 g/dL Total bilirubin ≤ 1.5 x upper limit of normal (ULN) Aspartate amino transferase (AST) ≤ 3 x ULN Alanine transaminase (ALT) ≤ 3 x ULN Creatinine clearance by Cockroft-Gault equation 60 mL/min Oxygen saturation ≥ 92% on room air Albumin ≥ 3 g/dL; Left ventricular ejection fraction ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University · Atlanta, Georgia
- University of Chicago · Chicago, Illinois
- University of Pennsylvania · Philadelphia, Pennsylvania
- Sarah Cannon Research Institute · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06055439 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CDH17-targeted therapy disqualifies patients from enrollment.
Does this trial require CDH17?
Yes, CDH17 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 85 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages